Anderson H - Search Results

1

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Anderson H, et al. J Clin Oncol. 1994 Sep;12(9):1821-6. doi: 10.1200/JCO.1994.12.9.1821. J Clin Oncol. 1994. PMID: 8083706 Clinical Trial.

2

Recombinant human GM-CSF in small cell lung cancer: a phase I/II study.

Anderson H, Gurney H, Thatcher N, Swindell R, Scarffe JH, Weiner J. Anderson H, et al. Recent Results Cancer Res. 1991;121:155-61. doi: 10.1007/978-3-642-84138-5_17. Recent Results Cancer Res. 1991. PMID: 1650015 Clinical Trial.

3

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.

Lund B, Ryberg M, Petersen PM, Anderson H, Thatcher N, Dombernowsky P. Lund B, et al. Among authors: anderson h. Ann Oncol. 1994 Nov;5(9):852-3. doi: 10.1093/oxfordjournals.annonc.a059018. Ann Oncol. 1994. PMID: 7848889 Free article. Clinical Trial. No abstract available.

4

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.

Betticher DC, Anderson H, Ranson M, Meely K, Oster W, Thatcher N. Betticher DC, et al. Among authors: anderson h. Br J Cancer. 1995 Dec;72(6):1551-5. doi: 10.1038/bjc.1995.546. Br J Cancer. 1995. PMID: 8519676 Free PMC article. Clinical Trial.

5

Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.

Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B. Thatcher N, et al. Among authors: anderson h. Clin Oncol (R Coll Radiol). 1995;7(5):293-9. doi: 10.1016/s0936-6555(05)80536-9. Clin Oncol (R Coll Radiol). 1995. PMID: 8580054 Clinical Trial.

6

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.

Anderson H, Thatcher N, Walling J, Hansen H. Anderson H, et al. Br J Cancer. 1996 Aug;74(3):460-2. doi: 10.1038/bjc.1996.382. Br J Cancer. 1996. PMID: 8695365 Free PMC article. Clinical Trial.

7

Chemotherapy in non-small cell lung cancer.

Thatcher N, Ranson M, Lee SM, Niven R, Anderson H. Thatcher N, et al. Among authors: anderson h. Ann Oncol. 1995;6 Suppl 1:83-94; discussion 94-5. doi: 10.1093/annonc/6.suppl_1.s83. Ann Oncol. 1995. PMID: 8695551 Review.

8

Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.

Thatcher N, Anderson H, Betticher DC, Ranson M. Thatcher N, et al. Among authors: anderson h. Anticancer Drugs. 1995 Dec;6 Suppl 6:39-48. doi: 10.1097/00001813-199512006-00007. Anticancer Drugs. 1995. PMID: 8718424 Review.

9

Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.

Thatcher N, Hopwood P, Anderson H. Thatcher N, et al. Among authors: anderson h. Eur J Cancer. 1997 Jan;33 Suppl 1:S8-13. doi: 10.1016/s0959-8049(96)00336-x. Eur J Cancer. 1997. PMID: 9166093 Review.

10

Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.

Thatcher N, Jayson G, Bradley B, Ranson M, Anderson H. Thatcher N, et al. Among authors: anderson h. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-6-S8-12. Semin Oncol. 1997. PMID: 9207309 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,122 results

Search Page

Filters